Introduction: Cancer cachexia occurs in cancer patients more frequently as the cancer progresses, with a negative impact on treatment outcomes. In this study, we sought to clarify the clinical impact of a cancer cachexia index (CXI) in patients with gastric cancer (GC) undergoing gastrectomy. Methods: Between January 2013 and December 2018, we reviewed data from 556 patients treated for GC at our hospital. CXI was calculated using skeletal muscle index (SMI), serum albumin, and neutrophil-lymphocyte ratios (NLR). Patients were divided into high (n = 414) or low CXI (n = 142) groups. We investigated the clinical impact of CXI in patients with GC undergoing gastrectomy. Results: Multivariate analyses of 5-year overall survival (OS) and cancer-specific survival (CSS) rates indicated that a low CXI was independently associated with unfavorable outcomes for patients with GC. In multivariate analyses, SMI was independent predictor of OS but not CSS. NLR was not an independent predictor of either OS or CSS. Complication incidences (≥ Clavien Dindo 3) were non-significantly higher in the low (vs. high) CXI group. Conclusion: CXI was a more valuable prognostic biomarker when compared with SMI or NLR in GC patients undergoing gastrectomy. We suggest that patients with low CXI values should be given more comprehensive treatment, including exercise and nutritional therapy to improve clinical outcomes.

Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013 Feb;10(2):90–9.
Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Primers. 2018 Jan 18;4(1):17105.
Takayama K, Atagi S, Imamura F, Tanaka H, Minato K, Harada T, et al. Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study. Support Care Cancer. 2016 Aug;24(8):3473–80.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394–424.
Sun L, Quan XQ, Yu S. An epidemiological survey of cachexia in advanced cancer patients and analysis on its diagnostic and treatment status. Nutr Cancer. 2015;67(7):1056–62.
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011 May;12(5):489–95.
Tisdale MJ. Biology of cachexia. J Natl Cancer Inst. 1997 Dec 3;89(23):1763–73.
Oñate-Ocaña LF, Aiello-Crocifoglio V, Gallardo-Rincón D, Herrera-Goepfert R, Brom-Valladares R, Carrillo JF, et al. Serum albumin as a significant prognostic factor for patients with gastric carcinoma. Ann Surg Oncol. 2007 Feb;14(2):381–9.
Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014 Jun;106(6):dju124.
Sakurai K, Kubo N, Tamura T, Toyokawa T, Amano R, Tanaka H, et al. Adverse effects of low preoperative skeletal muscle mass in patients undergoing gastrectomy for gastric cancer. Ann Surg Oncol. 2017 Sep;24(9):2712–9.
Jafri SH, Previgliano C, Khandelwal K, Shi R. Cachexia index in advanced non-small-cell lung cancer patients. Clin Med Insights Oncol. 2015;9:87–93.
Go SI, Park MJ, Park S, Kang MH, Kim HG, Kang JH, et al. Cachexia index as a potential biomarker for cancer cachexia and a prognostic indicator in diffuse large B-cell lymphoma. J Cachexia Sarcopenia Muscle. 2021 Dec;12(6):2211–9.
Akaoka M, Haruki K, Taniai T, Yanagaki M, Igarashi Y, Furukawa K, et al. Clinical significance of cachexia index in patients with hepatocellular carcinoma after hepatic resection. Surg Oncol. 2022 Dec;45:101881.
Hamura R, Haruki K, Shirai Y, Tanji Y, Taniai T, Okui N, et al. Preoperative cachexia index can predict the prognosis of extrahepatic biliary tract cancer after resection. Surg Oncol. 2022 Sep;44:101825.
Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009 Aug;250(2):187–96.
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition)Gastric Cancer. 2021 Jan;24(1):1–21.
Gong C, Wan Q, Zhao R, Zuo X, Chen Y, Li T. Cachexia index as a prognostic indicator in patients with gastric cancer: a retrospective study. Cancers. 2022 Sep 10;14(18):4400.
Wan Q, Yuan Q, Zhao R, Shen X, Chen Y, Li T, et al. Prognostic value of cachexia index in patients with colorectal cancer: a retrospective study. Front Oncol. 2022;12:984459.
Goh MJ, Kang W, Jeong WK, Sinn DH, Gwak GY, Paik YH, et al. Prognostic significance of cachexia index in patients with advanced hepatocellular carcinoma treated with systemic chemotherapy. Sci Rep. 2022 May 10;12(1):7647.
Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013 Apr 20;31(12):1539–47.
Iritani S, Imai K, Takai K, Hanai T, Ideta T, Miyazaki T, et al. Skeletal muscle depletion is an independent prognostic factor for hepatocellular carcinoma. J Gastroenterol. 2015 Mar;50(3):323–32.
Nakamura N, Hara T, Shibata Y, Matsumoto T, Nakamura H, Ninomiya S, et al. Sarcopenia is an independent prognostic factor in male patients with diffuse large B-cell lymphoma. Ann Hematol. 2015 Dec;94(12):2043–53.
van Baar H, Winkels RM, Brouwer JGM, Posthuma L, Bours MJL, Weijenberg MP, et al. Associations of abdominal skeletal muscle mass, fat mass, and mortality among men and women with stage I-III colorectal cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American association for cancer research, cosponsored by the American society of preventive oncology. Cancer Epidemiol Biomarkers Prev. 2020 May;29(5):956–65.
Sakurai K, Kubo N, Tamamori Y, Aomatsu N, Nishii T, Tachimori A, et al. Depletion of skeletal muscle mass adversely affects long-term outcomes for men undergoing gastrectomy for gastric cancer. PLoS One. 2021;16(8):e0256365.
Tabara Y, Setoh K, Kawaguchi T, Matsuda F. Skeletal muscle mass index is independently associated with all-cause mortality in men: the Nagahama study. Geriatr Gerontol Int. 2022 Nov;22(11):956–60.
Lieffers JR, Bathe OF, Fassbender K, Winget M, Baracos VE. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br J Cancer. 2012 Sep 4;107(6):931–6.
Fukuda Y, Yamamoto K, Hirao M, Nishikawa K, Nagatsuma Y, Nakayama T, et al. Sarcopenia is associated with severe postoperative complications in elderly gastric cancer patients undergoing gastrectomy. Gastric Cancer. 2016 Jul;19(3):986–93.
Tegels JJ, van Vugt JL, Reisinger KW, Hulsewé KW, Hoofwijk AG, Derikx JP, et al. Sarcopenia is highly prevalent in patients undergoing surgery for gastric cancer but not associated with worse outcomes. J Surg Oncol. 2015 Sep;112(4):403–7.
Kuwada K, Kuroda S, Kikuchi S, Yoshida R, Nishizaki M, Kagawa S, et al. Sarcopenia and comorbidity in gastric cancer surgery as a useful combined factor to predict eventual death from other causes. Ann Surg Oncol. 2018 May;25(5):1160–6.
Zhou H, Yi W, Zhang J, Wang W, Wang Y, Gao W, et al. Short- and long-term outcomes of LigaSure versus conventional surgery for curative gastric cancer resection: a matched pair analysis. Gastric Cancer. 2015 Oct;18(4):843–9.
Shibao K, Honda S, Adachi Y, Kohi S, Kudou Y, Matayoshi N, et al. An advanced bipolar device helps reduce the rate of postoperative pancreatic fistula in laparoscopic gastrectomy for gastric cancer patients: a propensity score-matched analysis. Langenbecks Arch Surg. 2022 Dec;407(8):3479–86.
Watanabe M, Okamura A, Toihata T, Yamashita K, Yuda M, Hayami M, et al. Recent progress in perioperative management of patients undergoing esophagectomy for esophageal cancer. Esophagus. 2018 Jul;15(3):160–4.
Ida S, Kumagai K, Nunobe S. Current status of perioperative nutritional intervention and exercise in gastric cancer surgery: a review. Ann Gastroenterol Surg. 2022 Mar;6(2):197–203.
Inokuchi M, Kojima K, Kato K, Sugita H, Sugihara K. Risk factors for post-operative pulmonary complications after gastrectomy for gastric cancer. Surg Infect. 2014 Jun;15(3):314–21.
Kiuchi J, Komatsu S, Ichikawa D, Kosuga T, Okamoto K, Konishi H, et al. Putative risk factors for postoperative pneumonia which affects poor prognosis in patients with gastric cancer. Int J Clin Oncol. 2016 Oct;21(5):920–6.
Ntutumu R, Liu H, Zhen L, Hu YF, Mou TY, Lin T, et al. Risk factors for pulmonary complications following laparoscopic gastrectomy: a single-center study. Medicine. 2016 Aug;95(32):e4567.
Kimura R, Moriyama T, Ohuchida K, Shindo K, Nagai S, Ohtsuka T, et al. Risk factors for postoperative pneumonia after laparoscopic gastrectomy in patients aged 75 years and over with gastric cancer. Asian J Endosc Surg. 2021 Jul;14(3):408–16.
Asklid D, Segelman J, Gedda C, Hjern F, Pekkari K, Gustafsson UO. The impact of perioperative fluid therapy on short-term outcomes and 5-year survival among patients undergoing colorectal cancer surgery - a prospective cohort study within an ERAS protocol. Eur J Surg Oncol. 2017 Aug;43(8):1433–9.
Loftus TJ, Stelton S, Efaw BW, Bloomstone J. A system-wide enhanced recovery program focusing on two key process steps reduces complications and readmissions in patients undergoing bowel surgery. J Healthc Qual. 2017 May/Jun;39(3):129–35.
You do not currently have access to this content.